Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease with appreciable morbidity and mortality. Current treatment comprises non-specific immunosuppression with many serious side-effects. Furthermore, response to therapy is often incomplete. More specific, and less toxic therapies are thus required. Interferon regulatory factor 5 (IRFS) polymorphisms are strongly associated in human genetic studies with an increased risk of developing SLE although the biological role of IRFS in lupus pathogenesis, if any, is not known. We have found that IRFS is absolutely required for disease development in a mouse model of SLE. In addition, a critical level of IRFS is required as IRFS heterozygous mice develop minimal disease manifestations. This suggests that IRFS might be a key therapeutic target in SLE. The application's objectives are to obtain a detailed understanding of the mechanisms whereby IRFS contributes to disease pathogenesis in SLE. The goal of specific aim 1 is to determine the role of IRFS in lupus-relevant immune responses by comparing the functional effects of homozygous and heterozygous IRFS deficiency on the response of dendritic cells and B cells to TLR stimuli including DNA- and RNA-containing immune complexes.
Specific aim 2 a will determine the generalizability of the IRFS role in SLE by evaluating the effect of IRFS-deficiency in additional lupus models.
Specific aim 2 b will determine to what extent the beneficial effect of IRFS-deficiency in lupus is TLR7- and/or TLR9-dependent or independent.
Specific aim 2 c will determine whether IRFS overexpression is able to induce disease in wildtype or autoimmune-prone mice.
Specific aim 3 will determine which IRFS-expressing cells are required for disease pathogenesis by using bone-marrow chimeras, and by deleting IRFS in specific cell types using a Cre-loxP approach with cell- specific Cre.
Specific aim 4 will determine whether deleting IRFS (in all cell types) after disease is established can reverse disease or prevent disease progression. This will be done also using a Cre-loxP approach but using an inducible Cre. It is anticipated that these studies will enhance the understanding of the role of IRFS in SLE pathogenesis and contribute to the development of new effective, safer and more specific therapies.
Genetic abnormalities in a protein called interferon regulatory factor S (IRFS) are found in many patients with the autoimmune disease systemic lupus erythematosus (SLE). We have found in an animal model of SLE that deficiency of IRFS prevents the development of disease. This suggests that IRFS might be a key therapeutic target in SLE
|Baum, Rebecca; Sharma, Shruti; Organ, Jason M et al. (2016) STING regulates abnormal bone formation induced by deficiency of DNase II. Arthritis Rheumatol :|
|Baum, Rebecca; NÃ¼ndel, Kerstin; Pawaria, Sudesh et al. (2016) Synergy between Hematopoietic and Radioresistant Stromal Cells Is Required for Autoimmune Manifestations of DNase II-/-IFNaR-/- Mice. J Immunol 196:1348-54|
|Garcia-Martinez, Irma; Santoro, Nicola; Chen, Yonglin et al. (2016) Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest 126:859-64|
|Giles, Josephine R; Kashgarian, Michael; Koni, Pandelakis A et al. (2015) B Cell-Specific MHC Class II Deletion Reveals Multiple Nonredundant Roles for B Cell Antigen Presentation in Murine Lupus. J Immunol 195:2571-9|
|Sharma, Shruti; Fitzgerald, Katharine A; Cancro, Michael P et al. (2015) Nucleic Acid-Sensing Receptors: Rheostats of Autoimmunity and Autoinflammation. J Immunol 195:3507-12|
|Pawaria, Sudesh; Moody, Krishna; Busto, Patricia et al. (2015) Cutting Edge: DNase II deficiency prevents activation of autoreactive B cells by double-stranded DNA endogenous ligands. J Immunol 194:1403-7|
|NÃ¼ndel, Kerstin; Green, Nathaniel M; Shaffer, Arthur L et al. (2015) Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses. J Immunol 194:2504-12|
|Baum, Rebecca; Sharma, Shruti; Carpenter, Susan et al. (2015) Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice. J Immunol 194:873-7|
|Sharma, Shruti; Campbell, Allison M; Chan, Jennie et al. (2015) Suppression of systemic autoimmunity by the innate immune adaptor STING. Proc Natl Acad Sci U S A 112:E710-7|
|Pawaria, Sudesh; Moody, Krishna L; Busto, Patricia et al. (2015) An unexpected role for RNA-sensing toll-like receptors in a murine model of DNA accrual. Clin Exp Rheumatol 33:S70-3|
Showing the most recent 10 out of 56 publications